iBio reported financial results for fiscal year 2024, with revenues of $0.2M, a 100% increase from 2023, and a reduced net loss of $24.9M compared to $65M in 2023. The company ended the year with $14.4M in cash and cash equivalents, strengthening its position through multiple strategic financial initiatives including a $15M PIPE financing and an $8.5M facility sale.The company made significant business progress, expanding its AI-powered technology stack with ShieldTx™ launch and selling its PD-1 asset to Otsuka for $1M upfront plus potential $52.5M in milestone payments. iBio also entered a collaboration with AstralBio in the cardiometabolic space and advanced its bispecific antibody programs, demonstrating 36% tumor reduction in preclinical studies.Key corporate developments included implementing a 1-for-20 reverse stock split, eliminating $13.2M in secured debt through the Texas facility sale, and strengthening leadership with new appointments. The company's auditor included a going concern paragraph in their opinion, reflecting ongoing financial challenges.

iBio reported financial results for fiscal year 2024, with revenues of $0.2M, a 100% increase from 2023, and a reduced net loss of $24.9M compared to $65M in 2023. The company ended the year with $14.4M in cash and cash equivalents, strengthening its position through multiple strategic financial initiatives including a $15M PIPE financing and an $8.5M facility sale.The company made significant business progress, expanding its AI-powered technology stack with ShieldTx™ launch and selling its PD-1 asset to Otsuka for $1M upfront plus potential $52.5M in milestone payments. iBio also entered a collaboration with AstralBio in the cardiometabolic space and advanced its bispecific antibody programs, demonstrating 36% tumor reduction in preclinical studies.Key corporate developments included implementing a 1-for-20 reverse stock split, eliminating $13.2M in secured debt through the Texas facility sale, and strengthening leadership with new appointments. The company's auditor included a going concern paragraph in their opinion, reflecting ongoing financial challenges.